Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: atrasentan Clear all

Conditions: Chronic Kidney Disease, Diabetic Nephropathy
Interventions: Placebo for Atrasentan 0.2 mg/mL solution, 0.25 mg Atrasentan QD, 0.75 mg Atrasentan QD, 1.75 mg Atrasentan QD; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: Atrasentan, Placebo, Zigakibart; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Alhambra, California • Glendale, California + 18 more

Conditions: Nephropathy, Diabetes
Interventions: Atrasentan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years to 75 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 9
States / cities: Laguna Hills, California • Santa Monica, California • Evergreen Park, Illinois + 6 more

Conditions: Chronic Kidney Disease, Diabetic Nephropathy
Interventions: Atrasentan, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 59
States / cities: Pell City, Alabama • Tempe, Arizona • Azusa, California + 48 more

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: Atrasentan, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more

Conditions: Prostatic Neoplasms
Interventions: Atrasentan; Drug
Lead sponsor: Abbott; Industry
Eligibility: 19 Years and older · Male only
Enrollment: 941 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 94
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 73 more

Conditions: Prostate Cancer, Adenocarcinoma of the Prostate
Interventions: Atrasentan, Zoledronic Acid (Zometa); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Male only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy, Primary IgAN, Nephritis IgA Type, Nephropathy IgA Type
Interventions: Drug: Atrasentan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Neptune City, New Jersey • Cincinnati, Ohio • Oklahoma City, Oklahoma + 1 more

Conditions: Chronic Kidney Disease, Diabetic Nephropathy
Interventions: Atrasentan, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 28
States / cities: Phoenix, Arizona • Tempe, Arizona • Azusa, California + 23 more

Conditions: Prostate Cancer
Interventions: atrasentan hydrochloride; Drug
Lead sponsor: Abbott; Industry
Eligibility: 19 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
Interventions: Atrasentan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 14
States / cities: Glendale, California • Los Angeles, California • San Dimas, California + 11 more

Conditions: Metastatic Cancer, Prostate Cancer
Interventions: atrasentan hydrochloride, docetaxel, prednisone, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Male only
Enrollment: 1,038 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 554
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more

Conditions: Brain and Central Nervous System Tumors
Interventions: atrasentan hydrochloride; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 10
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 7 more

Conditions: Endothelial Dysfunction
Interventions: atrasentan; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostatic Neoplasms
Interventions: Atrasentan; Drug
Lead sponsor: Abbott; Industry
Eligibility: 19 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 24
States / cities: Homewood, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 19 more

Conditions: Kidney Cancer
Interventions: atrasentan hydrochloride; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 177
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 116 more

Conditions: Prostate Cancer
Interventions: Atrasentan; Drug
Lead sponsor: Abbott; Industry
Eligibility: 19 Years and older · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 79
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 66 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: atrasentan hydrochloride, doxil; Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 6
States / cities: Macon, Georgia • Louisville, Kentucky • Germantown, Tennessee + 2 more

Conditions: IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Interventions: atrasentan; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Immunoglobulin A Nephropathy
Interventions: No intervention, Other treatment, Iptacopan, Atrasentan; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer, Adenocarcinoma
Interventions: Atrasentan; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 7
States / cities: Marina del Rey, California • Torrance, California • Aventura, Florida + 4 more

Search by objective public record fields.

A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors

Atrasentan in Patients With IgA Nephropathy

Atrasentan Spermatogenesis and Testicular Function

Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer

Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy

Atrasentan in Treating Patients With Prostate Cancer

Atrasentan in Patients With Proteinuric Glomerular Diseases

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma

Correlation of Endothelial Function and Early Coronary Artery Disease in Humans

Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure

Atrasentan in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

A Long Term Safety Study With Atrasentan